Your browser doesn't support javascript.
loading
Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo.
Jansen, Jade; Kroeze, Stefanie; Man, Shirley; Andreini, Matteo; Bakker, Jan-Willem; Zamperini, Claudio; Tarditi, Alessia; Kootstra, Neeltje A; Geijtenbeek, Teunis B H.
Afiliação
  • Jansen J; Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam , Amsterdam, the Netherlands.
  • Kroeze S; Amsterdam Institute for Infection and Immunity , Amsterdam, the Netherlands.
  • Man S; Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam , Amsterdam, the Netherlands.
  • Andreini M; Amsterdam Institute for Infection and Immunity , Amsterdam, the Netherlands.
  • Bakker J-W; Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam , Amsterdam, the Netherlands.
  • Zamperini C; Amsterdam Institute for Infection and Immunity , Amsterdam, the Netherlands.
  • Tarditi A; First Health Pharmaceuticals B.V , Amsterdam, the Netherlands.
  • Kootstra NA; First Health Pharmaceuticals B.V , Amsterdam, the Netherlands.
  • Geijtenbeek TBH; First Health Pharmaceuticals B.V , Amsterdam, the Netherlands.
Microbiol Spectr ; 12(1): e0318023, 2024 Jan 11.
Article em En | MEDLINE | ID: mdl-38051053
IMPORTANCE: HIV-1 continues to be a major global health challenge. Current HIV-1 treatments are effective but need lifelong adherence. An HIV-1 cure should eliminate the latent viral reservoir that persists in people living with HIV-1. Different methods have been investigated that focus on reactivation and subsequent elimination of the HIV-1 reservoir, and it is becoming clear that a combination of compounds with different mechanisms of actions might be more effective. Here, we target two host factors, inhibitor of apoptosis proteins that control apoptosis and the DEAD-box helicase DDX3, facilitating HIV mRNA transport/translation. We show that targeting of these host factors with SMAC mimetics and DDX3 inhibitors induce reversal of viral latency and eliminate HIV-1-infected cells in vitro and ex vivo.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Revista: Microbiol Spectr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Revista: Microbiol Spectr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos